Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Denver Mayor Orders Police to Protect Protesters, Restricts ICE Access to City Property 
Pentagon to Halt Ivy League Programs for U.S. Military Officers Starting 2026 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Australia Launches Royal Commission Into Antisemitism After Bondi Beach Hanukkah Attack 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Venezuela Amnesty Law Frees Nearly 2,200 Prisoners, Says Jorge Arreaza 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
U.S. Plans 4,500 Monthly Refugee Admissions for White South Africans Amid Policy Debate 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for all currently approved CAR-T cell therapies, a move expected to improve patient access to these advanced cancer treatments.
CAR-T cell therapy, a form of gene therapy used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, involves reprogramming a patient’s T-cells to attack cancer cells. Despite serious side effects, including cytokine release syndrome and neurological toxicities, the FDA concluded that existing labeling and boxed warnings are sufficient to communicate these risks without the need for REMS.
This regulatory update affects therapies including Bristol-Myers Squibb’s Breyanzi and Abecma (developed with 2seventy bio), Johnson & Johnson’s Carvykti (with Legend Biotech), Novartis’ Kymriah, and Gilead’s Tecartus and Yescarta. Gilead confirmed label updates to reflect the FDA’s decision, stating it would ease the burden on healthcare providers and expand access to potentially curative treatments.
Bristol-Myers Squibb echoed this sentiment, emphasizing its commitment to breaking down barriers to CAR-T access. These therapies have been a breakthrough in oncology, offering new hope for patients with few alternatives.
In January 2024, the FDA had mandated additional safety warnings for CAR-T drugs following reports of secondary T-cell malignancies, including leukemia and lymphoma. Despite these risks, the agency now believes they can be effectively managed through existing safety measures.
With this change, the FDA aims to streamline access to CAR-T therapies while maintaining patient safety, reinforcing its support for innovation in personalized cancer treatment. This decision marks a significant regulatory shift that could accelerate the adoption of CAR-T across oncology care.
